Silence Therapeutics plc (SLNCF) Net margin 2022–2025
Silence Therapeutics plc (SLNCF) net profit margin by fiscal year — reported net income divided by reported revenue.
-15851.9%FY2025 · since FY2022: -232.4% → -15851.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -15851.9% | -15747.1 pp |
| FY2024 | -104.7% | +66.6 pp |
| FY2023 | -171.4% | +61.1 pp |
| FY2022 | -232.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SLNCF financial trends
SLNCF RevenueSLNCF Net incomeSLNCF Gross profitSLNCF Gross marginSLNCF Operating incomeSLNCF Operating marginSLNCF Operating cash flowSLNCF Free cash flowSLNCF Capital expendituresSLNCF Return on equitySLNCF Stock buybacksSLNCF Dividends paidSLNCF Total assetsSLNCF Total liabilitiesSLNCF Shareholders’ equitySLNCF overview →